Thermo Fisher Scientific has opened a new sterile drug facility in Singapore to support customers to deliver new medicines and vaccines in the Asia-Pacific market. The new facility marks a significant milestone and investment in pandemic preparedness for Singapore, which is fast emerging as a biomedical hub in the Asia-Pacific region.
With help from the Singapore Economic Development Board (EDB), in alignment with the government’s investment in preparedness for future health emergencies, the current good manufacturing practices (cGMP) facility will provide rapid vaccine fill-finish capabilities along with Thermo Fisher’s end-to-end pharmaceutical development and manufacturing services.
The new facility includes a high-speed, fully automated aseptic fill-finish line for small and large molecules. The strategic investment in Singapore complements new research capabilities at Thermo Fisher Scientific’s customer experience center and bioprocess design center, two other operational lab facilities that showcase the latest bioprocessing, life science, and analytical technologies.
With more than 250 products across diverse fields including molecular biology, genetic analysis and sequencing, chromatography and mass spectrometry, and cell therapy, the customer experience center features an extensive product portfolio for Asia. In addition, the bioprocess design center provides expertise in bioprocessing and process scale-up to support scientists and engineers with education and customized services to accelerate process development.
“We are committed to serving as a reliable partner to the Asia-Pacific region and the world,” said Michel Lagarde, executive vice president and chief operating officer at Thermo Fisher Scientific. “This new site is an important extension of Thermo Fisher’s robust sterile fill-finish global network. With this expansion, we are strategically prepared, more than ever, to respond to our customers’ needs by supporting the accelerated delivery of critical vaccines and medicines to patients.”
